Logo image of DARE

DARE BIOSCIENCE INC (DARE) Stock Fundamental Analysis

USA - NASDAQ:DARE - US23666P2002 - Common Stock

2.18 USD
+0.03 (+1.4%)
Last: 10/3/2025, 8:00:01 PM
2.1503 USD
-0.03 (-1.36%)
After Hours: 10/3/2025, 8:00:01 PM
Fundamental Rating

3

Taking everything into account, DARE scores 3 out of 10 in our fundamental rating. DARE was compared to 196 industry peers in the Pharmaceuticals industry. DARE has a bad profitability rating. Also its financial health evaluation is rather negative. DARE has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

DARE had negative earnings in the past year.
DARE had a positive operating cash flow in the past year.
DARE had negative earnings in each of the past 5 years.
DARE had negative operating cash flow in 4 of the past 5 years.
DARE Yearly Net Income VS EBIT VS OCF VS FCFDARE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

DARE has a Return On Assets of -9.00%. This is in the better half of the industry: DARE outperforms 67.86% of its industry peers.
Industry RankSector Rank
ROA -9%
ROE N/A
ROIC N/A
ROA(3y)-76.89%
ROA(5y)-132.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DARE Yearly ROA, ROE, ROICDARE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K -4K -6K -8K

1.3 Margins

DARE's Gross Margin of 108.60% is amongst the best of the industry. DARE outperforms 99.49% of its industry peers.
The Profit Margin and Operating Margin are not available for DARE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 108.6%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DARE Yearly Profit, Operating, Gross MarginsDARE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50K -100K -150K -200K

More info and screens

3

2. Health

2.1 Basic Checks

DARE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, DARE has more shares outstanding
The number of shares outstanding for DARE has been reduced compared to 5 years ago.
Compared to 1 year ago, DARE has a worse debt to assets ratio.
DARE Yearly Shares OutstandingDARE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
DARE Yearly Total Debt VS Total AssetsDARE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -17.39, we must say that DARE is in the distress zone and has some risk of bankruptcy.
DARE's Altman-Z score of -17.39 is on the low side compared to the rest of the industry. DARE is outperformed by 78.57% of its industry peers.
DARE has a debt to FCF ratio of 1.20. This is a very positive value and a sign of high solvency as it would only need 1.20 years to pay back of all of its debts.
DARE's Debt to FCF ratio of 1.20 is amongst the best of the industry. DARE outperforms 94.90% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 1.2
Altman-Z -17.39
ROIC/WACCN/A
WACC9.68%
DARE Yearly LT Debt VS Equity VS FCFDARE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 0.56 indicates that DARE may have some problems paying its short term obligations.
With a Current ratio value of 0.56, DARE is not doing good in the industry: 90.82% of the companies in the same industry are doing better.
DARE has a Quick Ratio of 0.56. This is a bad value and indicates that DARE is not financially healthy enough and could expect problems in meeting its short term obligations.
DARE has a Quick ratio of 0.56. This is amonst the worse of the industry: DARE underperforms 89.80% of its industry peers.
Industry RankSector Rank
Current Ratio 0.56
Quick Ratio 0.56
DARE Yearly Current Assets VS Current LiabilitesDARE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for DARE have decreased strongly by -91.96% in the last year.
Looking at the last year, DARE shows a very negative growth in Revenue. The Revenue has decreased by -99.65% in the last year.
EPS 1Y (TTM)-91.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.61%
Revenue 1Y (TTM)-99.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-195.45%

3.2 Future

Based on estimates for the next years, DARE will show a very strong growth in Earnings Per Share. The EPS will grow by 90.39% on average per year.
Based on estimates for the next years, DARE will show a very strong growth in Revenue. The Revenue will grow by 189.30% on average per year.
EPS Next Y-204.04%
EPS Next 2Y57.81%
EPS Next 3Y81.13%
EPS Next 5Y90.39%
Revenue Next Year-51.68%
Revenue Next 2Y392.65%
Revenue Next 3Y261.34%
Revenue Next 5Y189.3%

3.3 Evolution

DARE Yearly Revenue VS EstimatesDARE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
DARE Yearly EPS VS EstimatesDARE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -100 -200 -300 -400 -500

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

DARE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 8.55, the valuation of DARE can be described as reasonable.
88.78% of the companies in the same industry are more expensive than DARE, based on the Price/Forward Earnings ratio.
DARE is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.32, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 8.55
DARE Price Earnings VS Forward Price EarningsDARE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

97.96% of the companies in the same industry are more expensive than DARE, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 4.89
EV/EBITDA N/A
DARE Per share dataDARE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

DARE's earnings are expected to grow with 81.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y57.81%
EPS Next 3Y81.13%

More info and screens

0

5. Dividend

5.1 Amount

DARE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DARE BIOSCIENCE INC

NASDAQ:DARE (10/3/2025, 8:00:01 PM)

After market: 2.1503 -0.03 (-1.36%)

2.18

+0.03 (+1.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-12 2025-11-12
Inst Owners6.71%
Inst Owner Change8.12%
Ins Owners0.75%
Ins Owner Change0%
Market Cap29.39M
Analysts80
Price Target10.97 (403.21%)
Short Float %1.84%
Short Ratio1.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2%
Min EPS beat(2)-19.49%
Max EPS beat(2)15.48%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-98.2%
Min Revenue beat(2)-104.71%
Max Revenue beat(2)-91.69%
Revenue beat(4)0
Avg Revenue beat(4)-99.03%
Min Revenue beat(4)-104.71%
Max Revenue beat(4)-91.69%
Revenue beat(8)1
Avg Revenue beat(8)-58.63%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.86%
PT rev (3m)-17.31%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8.07%
EPS NY rev (1m)21.91%
EPS NY rev (3m)23.52%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-33.33%
Revenue NY rev (1m)-90.7%
Revenue NY rev (3m)-93.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 8.55
P/S 328.34
P/FCF 4.89
P/OCF 4.36
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.15
EYN/A
EPS(NY)0.26
Fwd EY11.7%
FCF(TTM)0.45
FCFY20.46%
OCF(TTM)0.5
OCFY22.92%
SpS0.01
BVpS-0.71
TBVpS-0.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -9%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 108.6%
FCFM 6719.11%
ROA(3y)-76.89%
ROA(5y)-132.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 1.2
Debt/EBITDA N/A
Cap/Depr 381.33%
Cap/Sales 807.82%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.56
Quick Ratio 0.56
Altman-Z -17.39
F-Score3
WACC9.68%
ROIC/WACCN/A
Cap/Depr(3y)1097.89%
Cap/Depr(5y)675.4%
Cap/Sales(3y)1956.65%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-91.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-129.61%
EPS Next Y-204.04%
EPS Next 2Y57.81%
EPS Next 3Y81.13%
EPS Next 5Y90.39%
Revenue 1Y (TTM)-99.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-195.45%
Revenue Next Year-51.68%
Revenue Next 2Y392.65%
Revenue Next 3Y261.34%
Revenue Next 5Y189.3%
EBIT growth 1Y23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y127.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y130.8%
OCF growth 3YN/A
OCF growth 5YN/A